Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Cash Flows

v2.4.1.9
Condensed Consolidated Statements of Cash Flows (USD $)
In Thousands, unless otherwise specified
3 Months Ended
Mar. 31, 2015
Mar. 31, 2014
Cash flows from operating activities:    
Net loss $ (12,535)us-gaap_ProfitLoss $ (7,370)us-gaap_ProfitLoss
Adjustments to reconcile net loss to net cash used in operating activities:    
Subsidiary shares issued for licences and expensed 513us-gaap_StockIssued1 0us-gaap_StockIssued1
Stock-based compensation expense 1,470us-gaap_ShareBasedCompensation 1,135us-gaap_ShareBasedCompensation
Noncash interest expense 188us-gaap_OtherNoncashExpense 515us-gaap_OtherNoncashExpense
Depreciation expense 6us-gaap_Depreciation 5us-gaap_Depreciation
Asset impairment and lease abandonment charges 0us-gaap_AssetImpairmentCharges 723us-gaap_AssetImpairmentCharges
Change in fair value of investments 215fbio_ChangeInFairValueOfShortTermInvestments 0fbio_ChangeInFairValueOfShortTermInvestments
Unrealized gain on marketable securities (2)us-gaap_TradingSecuritiesUnrealizedHoldingGainLoss 0us-gaap_TradingSecuritiesUnrealizedHoldingGainLoss
Realized gain on marketable securities (1)us-gaap_TradingSecuritiesRealizedGainLoss 0us-gaap_TradingSecuritiesRealizedGainLoss
Changes in operating assets and liabilities:    
Prepaid expenses and other currents assets 22us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets (12)us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
Interest payable (2)us-gaap_IncreaseDecreaseInInterestPayableNet (84)us-gaap_IncreaseDecreaseInInterestPayableNet
Accounts payable and accrued expenses 1,853us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities (588)us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
Other long term liabilities (500)us-gaap_IncreaseDecreaseInOtherOperatingLiabilities 0us-gaap_IncreaseDecreaseInOtherOperatingLiabilities
End of term charge Hercules Note 0us-gaap_IncreaseDecreaseInOtherAccountsPayable (398)us-gaap_IncreaseDecreaseInOtherAccountsPayable
Other (61)us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet 0us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet
Net cash used in operating activities (8,834)us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations (6,074)us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
Cash flows from investing activities:    
Purchase of investments, long-term 0us-gaap_PaymentsToAcquireLongtermInvestments (250)us-gaap_PaymentsToAcquireLongtermInvestments
Purchase of license (1,250)us-gaap_PaymentsToAcquireIntangibleAssets 0us-gaap_PaymentsToAcquireIntangibleAssets
Payment to related party - CB Pharma Acquisitions Corp (108)us-gaap_RepaymentsOfRelatedPartyDebt 0us-gaap_RepaymentsOfRelatedPartyDebt
Net cash used in investing activities (1,358)us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations (250)us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
Cash flows from financing activities:    
Proceeds from issuance of Common Stock 0us-gaap_ProceedsFromIssuanceOfCommonStock 481us-gaap_ProceedsFromIssuanceOfCommonStock
Payment of costs related to the issuance of Common Stock 0us-gaap_PaymentsOfStockIssuanceCosts (32)us-gaap_PaymentsOfStockIssuanceCosts
Proceeds from the exercise of stock options 216us-gaap_ProceedsFromStockOptionsExercised 0us-gaap_ProceedsFromStockOptionsExercised
Payment of Hercules Note 0us-gaap_RepaymentsOfNotesPayable (13,655)us-gaap_RepaymentsOfNotesPayable
Proceeds from IDB Note 0us-gaap_ProceedsFromNotesPayable 14,009us-gaap_ProceedsFromNotesPayable
Payment of debt issue costs associated with IDB Note 0us-gaap_PaymentsOfDebtIssuanceCosts (9)us-gaap_PaymentsOfDebtIssuanceCosts
Proceeds from NSC Note 10,000us-gaap_ProceedsFromUnsecuredNotesPayable 0us-gaap_ProceedsFromUnsecuredNotesPayable
Payment of debt issue costs associated with NSC Note (855)us-gaap_PaymentsOfFinancingCosts 0us-gaap_PaymentsOfFinancingCosts
Transfer of restricted cash 0us-gaap_IncreaseDecreaseInRestrictedCash (14,009)us-gaap_IncreaseDecreaseInRestrictedCash
Net cash provided by/(used in) financing activities 9,361us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations (13,215)us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
Decrease in cash and cash equivalents (831)us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease (19,539)us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease
Cash and cash equivalents—beginning of period 49,759us-gaap_CashAndCashEquivalentsAtCarryingValue 99,521us-gaap_CashAndCashEquivalentsAtCarryingValue
Cash and cash equivalents—end of period 48,928us-gaap_CashAndCashEquivalentsAtCarryingValue 79,982us-gaap_CashAndCashEquivalentsAtCarryingValue
Supplemental disclosure of cash flow information:    
Cash paid for interest 80us-gaap_InterestPaid 534us-gaap_InterestPaid
Supplemental disclosure of non-cash financing and investing activities:    
Issuance of Restricted Stock $ 1us-gaap_StockIssuedDuringPeriodValueIssuedForServices $ 4us-gaap_StockIssuedDuringPeriodValueIssuedForServices